Lantus is one of the world's best selling drugs, clocking $8 billion per year in revenue, and a cornerstone of Sanofi's (NYSE: SNY) business. Unfortunately for investors in the French pharma, that flagship product is soon to be under attack from a generic biosimilar version from Eli Lilly (NYSE: LLY) and Boehringer Ingelhiem. The CHMP recommended European approval for Abasria, with a a likely "yes" nod from regulators in the coming months.

Sanofi isn't taking the threat to its diabetes business laying down. It has a next generation insulin called Toujeo on the way that looks to improve on Lantus. The company also recently signed a deal with Medtronic (NYSE: MDT) to develop new combined drug and device treatments and offer care management services for the disease.

In this episode of Market Check-Up, the Motley Fool's health care focused investing show, analysts David Williamson and Michael Douglass, discuss the news of the Medtronic and Sanofi deal, and what it all means for investors.

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.


David Williamson has no position in any stocks mentioned. Michael Douglass has no position in any stocks mentioned. The Motley Fool owns shares of Medtronic. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.